Mucosal Melanoma: a Literature Review
- 469 Downloads
Purpose of review
Mucosal melanoma is of great interest due to its aggressive behavior and less favorable prognosis. The literature is mainly case reports and case series. Here, we will collect the knowledge on mucosal melanoma from the last decade and review the literature. The main focus is being site-specific clinical features, treatment, and prognosis.
The use of immunotherapy gain ground as for others subsets of melanoma. Anti-CTLA-4 and anti-PD-1/ PD-L1 blockade in mucosal melanoma have been evaluated in recent studies. Clinical trials are ongoing.
The etiology of mucosal melanomas remains unknown. Head and neck mucosal melanomas are most common. Wide excision surgery is the treatment of choice. The effect of adjuvant therapy on survival remains questionable due to the limited knowledge. Radiotherapy seems to give better local control. The overall five-year survival rate for mucosal melanomas is 0–45%. Recent data indicates that this may be improved by the immunotherapy in the years to come.
KeywordsMucosal melanoma Treatment Surgery Immunotherapy Checkpoint inhibitors CTLA-4 PD-1 PD-L1 Ipilimumab Nivolumab Pembrolizumab
Compliance with Ethical Standards
Conflict of Interest
Simon Skovsted Yde, Pia Sjoegren, Martin Heje, and Lars B. Stolle declare they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.López F, Rodrigo JP, Cardesa A, Triantafyllou A, Devaney KO, Mendenhall WM, et al. Update on primary head and neck mucosal melanoma. Head & Neck, 2016, 38.1: 147-155.Google Scholar
- 8.Tacastacas JD, Bray J, Cohen YK, Arbesman J, Kim J, Koon HB, et al. Update on primary mucosal melanoma. J Am Dermatology. 2014;71:366–75.Google Scholar
- 9.Sheng X, Kong Y, Li Y, Zhang Q, Si L, Cui C, et al. GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis. Eur J Cancer. 2016;65:156–63.Google Scholar
- 10.Itoh M, Goto A, Wakasugi H, Yoshida Y, Matsunaga Y, Fujii K, et al. Anorectal melanoma with a KIT-activating mutation, which is a target for tyrosine kinase inhibitor. Int J Clin Oncol. 2011;16:428–34.Google Scholar
- 11.• Angelo SPD, Larkin J, Sosman JA, Lebb C, Brady B, Neyns B, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma : a pooled analysis. J Clin Oncol. 2017;35:226–35. For mucosal melanoms, nivolumab combined with ipilimumab seemed to have greater efficacy than either agent alone. However, the incidence of grades 3 or 4 treatment-related adverse events was 40.0% for combination therapy. Patient selection is of great importance. PubMedGoogle Scholar
- 12.Boulaadas M, Benazzou S, Mourtada F, Sefiani S, Nazih N, Essakalli L, et al. Primary oral malignant melanoma. J og craniofacial Surg. 2007;18:1059–61.Google Scholar
- 13.Auluck A, Zhang L, Path DO, Frcd C. Primary malignant melanoma of maxillary gingiva —a case report and review of the literature. Clin Pract. 2008;74:367–71.Google Scholar
- 17.Umeda M, Murata M, Suzuki H, Yanagida T, Shibuya Y, Komori T. A case of malignant melanoma of the oral cavity alive with liver metastasis for a long period with administration of a biologic response modifier, OK432. Kobe J Med Sci. 2010;56:140–7.Google Scholar
- 46.Mcnab P, Quigley B, Mendoza T, Hakam A, Khalil F, Case Report FM. The histogenic origin of melanoma arising in respiratory epithelium of a teratomatous germ cell tumor of the mediastinum : an enigma unraveled from an unlikely source. Int J Clin Exp Pathol. 2011;5:982–90.Google Scholar
- 49.Aggarwal S, Kaushal V, Singla S, Sen R. Primary glottic malignant melanoma of the larynx (PGMML): a very rare entity. BMJ Case Rep. 2015:1–4.Google Scholar
- 52.Karmiris K, Roussomoustakaki M, Tzardi M, Romanos J, Grammatikakis J, Papadakis M, et al. Ileal malignant melanoma causing intussusception: report of a case. Surg Today. 2007;37:506–9.Google Scholar
- 59.Casey S, Dvorkin L, Alsanjari N, Dezso B. Symptomatic malignant melanoma presenting as multiple gastrointestinal polyps. BMJ Case Rep 2011;bcr0320102866.Google Scholar
- 61.Yamamoto S, Makuuchi H, Kumaki N, Ozawa S, Shimada H, Chino O, et al. A long surviving case of multiple early stage primary malignant melanoma of the esophagus and a review of the literature. Tokai J Exp Clin Med. 2015;40:90–5.Google Scholar
- 63.Prosvicova J, Lukesova S, Kopecky J, Grim J, Papik Z, Kolarova R, et al. Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: a case report. Biomed Pap. 2015;159:695–7.Google Scholar
- 65.Cubukcu E, Olmez OF, Ozkan K, Pekgoz M, Ugras N, Deligonul A, et al. Malignant melanoma of the stomach in an elderly patient. Turkish. J Gastroenterol. 2014;25:295–6.Google Scholar
- 68.Grenader T, Isacson R, Reinus C, Rosengarten O, Barenholz O, Hyman J, et al. Primary amelanotic melanoma of the vagina. Oncol Res Treat. 2008;31:474–6.Google Scholar
- 69.Baderca F, Cojocaru S, Lazǎr E, Lǎzureanu C, Lighezan R, Alexa A, et al. Amelanotic vulvar melanoma: case report and review of the literature. Romanian J Morphol Embryol. 2008;49:219–28.Google Scholar
- 78.Dogu GG, Yaren A, Tuncay L, Senturk N, Zumrutbas AE, Taskoylu BY, et al. Primary malignant melanoma of the penis: a case report. Med Oncol. 2012;29(2):1300–3.Google Scholar
- 79.McLoughlin LC, Davis NF, Cham A, Mohan P. Primary penile melanoma with an incidental renal oncocytoma. BMJ Case Rep. 2013:1–3.Google Scholar
- 81.van Geel AN, den Bakker MA, Kirkels W, Horenblas S, Kroon BBR, de Wilt JHW, et al. Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature. Urology. 2007;70:143–7.Google Scholar
- 83.Bartell HL, Bedikian AY, Papadopoulos NE, Dett TK, Ballo MT, Myers JN, et al. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck. 2008;30:1592–8.Google Scholar
- 85.Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caracò C, Curvietto M, et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother. 2014;63:675–83.Google Scholar
- 86.• Ascierto PA, Vanella V, Maria A, Festino G, Palla M, Simeone E, et al. Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase : a case report from a phase III trial. Cancer Immunol Immunother. 2016;65:1395–400. A case from a phase III trail (CheckMate 066) who achieved a partial response to dacarbazine, followed by a durable complete response with nivolumab monotherapy treatment. The outcome of the complete trail is of great interest. CrossRefPubMedGoogle Scholar
- 87.• Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, et al. The efficacy of Anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016;122:3354–62. This multi-institutional, retrospective cohort analysis identifies response rates to PD-1 blockade comparable to the published rates in patients with cutaneous melanoma and support the routine use of PD-1 blockade in clinical practice for mucosal melanomas. CrossRefPubMedPubMedCentralGoogle Scholar